Listing 1 - 10 of 10 |
Sort by
|
Choose an application
Choose an application
Choose an application
Saccharin. --- Sugar trade --- Imports
Choose an application
Aldehydes. --- Aldehydes. --- Aldehydes. --- Aldehydsäuren. --- Aldéhydes. --- Chemische Analyse. --- Monosaccharide. --- Saccharin. --- Saccharin. --- Saccharin. --- Saccharine. --- Trennverfahren.
Choose an application
Saccharin. --- Polymers. --- Glycogen --- 66.095.26 <063> --- Polymerization --- -Saccharides --- -Sugars --- Polymerisation --- Polymers --- Polymers and polymerization --- Synthesis of polymers --- Chemical reactions --- Polymer --- Saccharin Calcium --- Saccharin Sodium --- Calcium, Saccharin --- metabolism. --- Polymerization--Congressen --- Congresses --- Synthesis --- Saccharides --- Polysaccharides --- Congresses. --- Metabolism --- -metabolism. --- 66.095.26 <063> Polymerization--Congressen --- -Polymer --- Saccharin --- Sugars --- metabolism
Choose an application
Byproducts --- Plasticizers --- Epoxy resins --- Equivalent weight --- Spectrograms --- Density ratio --- Saccharin --- Theories --- Tests --- Viscosity --- Byproducts --- Plasticizers --- Epoxy resins --- Equivalent weight --- Spectrograms --- Density ratio --- Saccharin --- Theories --- Tests --- Viscosity
Choose an application
The crystalline state is the most commonly used essential solid active pharmaceutical ingredient (API). The characterization of pharmaceutical crystals encompasses many scientific disciplines, but the core is crystal structure analysis, which reveals the molecular structure of essential pharmaceutical compounds. Crystal structure analysis provides important structural information related to the API's wide range of physicochemical properties, such as solubility, stability, tablet performance, color, and hygroscopicity. This book entitled “Pharmaceutical Crystals"" focuses on the relationship between crystal structure and physicochemical properties. In particular, the new crystal structure of pharmaceutical compounds involving multi-component crystals, such as co-crystals, salts, and hydrates, and polymorph crystals are reported. Such crystal structures were investigated in the latest studies that combined morphology, spectroscopic, theoretical calculation, and thermal analysis with crystallographic study. This book highlights the importance of crystal structure information in many areas of pharmaceutical science and presents current trends in the structure–property study of pharmaceutical crystals. The Guest Editors of this book hope the readers enjoy a wide variety of recent studies on Pharmaceutical Crystals.
crystal structure analysis --- n/a --- famotidine --- solution crystallization --- salt optimization --- structure determination from powder diffraction data --- Hirshfeld surface analysis --- DFT --- molecular docking study --- melting diagram --- dehydration --- hygroscopicity --- HBV --- Benzodioxole --- pharmaceutical crystals --- 4-b]indol-4-one --- pyrimidin-4(3H)-one --- liquid assisted grinding --- HOMO-LUMO --- dissolution --- cocrystal formation --- Raman spectroscopy --- carbamazepine --- hydrogen bonding --- 3 --- ondansetron --- physicochemical properties --- solubility --- succinic acid --- cocrystal --- adefovir dipivoxil --- hepatitis B --- polymorphs --- hydrogen-bond-acceptance ability --- DFT study --- Nitrofurantoin–4-dimethylaminopyridine (NF-DMAP) salt --- photostability --- on-line monitoring --- 5-dihydro-4H-pyrimido[5 --- Imidazole --- Semicarbazone --- crystal habit --- Crystal structure --- solvent-mediated polymorphic transformation --- ticagrelor --- hydrate --- pharmaceutical cocrystal --- malonic acid --- 1H-indole --- reactivity descriptors --- famoxadone --- crystal structure --- dicarboxylic acid --- hydrogen bond --- saccharin --- Nitrofurantoin-4-dimethylaminopyridine (NF-DMAP) salt
Choose an application
Women and men have probably never been concerned as much by their health as during this COVID-19 pandemic. In this context, lifestyle habits continue to be promoted as allies for daily prevention against diseases. This is valid also for metabolic diseases, among which many affect the liver and are risk factors for aggravating the disease course of COVID-19. In fact, liver diseases are currently a major global health problem. There is a huge range of liver diseases and non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic condition, which in some patients progresses to cirrhosis and liver cancer. Currently, substantial efforts are being made to better understand NAFLD, especially, because there is no U.S. Food and Drug Administration (FDA)-approved pharmacological therapy. To explore this disease, metabolomics is the most recently developed omics technology after genomics, transcriptomics, and proteomics. Metabolomics is the large-scale analysis of molecules, known as metabolites that are intermediate or end products of metabolism found within cells, tissues, and biofluids. This technology has a very high potential to identify biomarker candidates for the future development of new therapeutics. The book features articles that address metabolomics technology and its use to document different liver functions and dysfunctions, with a major focus on NAFLD.
Medicine --- nonalcoholic fatty liver disease --- nonalcoholic steatohepatitis --- Fibrosis --- Liver biopsy --- Genomics --- Metabolomics --- Proteomics --- Transcriptomics --- nicotinamide --- NAFLD --- steatosis --- heat stress --- primary mouse hepatocytes --- metabolic profile --- GC-MS --- multivariate statistical analysis --- arachidonic acid --- docosahexaenoic acid --- inflammation --- fibrosis --- lipidomics --- mass spectrometry --- in vitro --- HepaRG --- sodium saccharin --- reference toxicants --- de novo lipogenesis --- carbohydrate response element-binding protein --- ChREBP --- diabetes --- glucose production --- glycogen --- glycolysis --- glycogen storage disease type I --- hexosamine --- pentose phosphate pathway --- acupuncture --- imflammation --- lipid metabolism --- oxidative stress --- metabolomics quantitative profiling --- 1H-NMR spectroscopy --- liver --- bile acids --- metabolomics --- rat plasma --- tandem mass spectrometry --- liquid chromatography --- acetaminophen --- hepatotoxicity --- biomarker --- premalignant --- alcoholic liver disease --- cholestasis --- cirrhosis --- NAFL --- NASH --- standard operating procedures --- urine --- blood --- feces --- tissue --- cells --- liver function --- nonalcoholic fatty liver --- liquid chromatography-mass spectrometry --- nuclear magnetic resonance spectroscopy --- metabolic pathway --- non-alcoholic fatty liver disease --- non-alcoholic steatohepatitis --- transcription factors --- metabolic stress --- lipid homeostasis --- glucose homeostasis
Choose an application
Women and men have probably never been concerned as much by their health as during this COVID-19 pandemic. In this context, lifestyle habits continue to be promoted as allies for daily prevention against diseases. This is valid also for metabolic diseases, among which many affect the liver and are risk factors for aggravating the disease course of COVID-19. In fact, liver diseases are currently a major global health problem. There is a huge range of liver diseases and non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic condition, which in some patients progresses to cirrhosis and liver cancer. Currently, substantial efforts are being made to better understand NAFLD, especially, because there is no U.S. Food and Drug Administration (FDA)-approved pharmacological therapy. To explore this disease, metabolomics is the most recently developed omics technology after genomics, transcriptomics, and proteomics. Metabolomics is the large-scale analysis of molecules, known as metabolites that are intermediate or end products of metabolism found within cells, tissues, and biofluids. This technology has a very high potential to identify biomarker candidates for the future development of new therapeutics. The book features articles that address metabolomics technology and its use to document different liver functions and dysfunctions, with a major focus on NAFLD.
nonalcoholic fatty liver disease --- nonalcoholic steatohepatitis --- Fibrosis --- Liver biopsy --- Genomics --- Metabolomics --- Proteomics --- Transcriptomics --- nicotinamide --- NAFLD --- steatosis --- heat stress --- primary mouse hepatocytes --- metabolic profile --- GC-MS --- multivariate statistical analysis --- arachidonic acid --- docosahexaenoic acid --- inflammation --- fibrosis --- lipidomics --- mass spectrometry --- in vitro --- HepaRG --- sodium saccharin --- reference toxicants --- de novo lipogenesis --- carbohydrate response element-binding protein --- ChREBP --- diabetes --- glucose production --- glycogen --- glycolysis --- glycogen storage disease type I --- hexosamine --- pentose phosphate pathway --- acupuncture --- imflammation --- lipid metabolism --- oxidative stress --- metabolomics quantitative profiling --- 1H-NMR spectroscopy --- liver --- bile acids --- metabolomics --- rat plasma --- tandem mass spectrometry --- liquid chromatography --- acetaminophen --- hepatotoxicity --- biomarker --- premalignant --- alcoholic liver disease --- cholestasis --- cirrhosis --- NAFL --- NASH --- standard operating procedures --- urine --- blood --- feces --- tissue --- cells --- liver function --- nonalcoholic fatty liver --- liquid chromatography-mass spectrometry --- nuclear magnetic resonance spectroscopy --- metabolic pathway --- non-alcoholic fatty liver disease --- non-alcoholic steatohepatitis --- transcription factors --- metabolic stress --- lipid homeostasis --- glucose homeostasis
Choose an application
Women and men have probably never been concerned as much by their health as during this COVID-19 pandemic. In this context, lifestyle habits continue to be promoted as allies for daily prevention against diseases. This is valid also for metabolic diseases, among which many affect the liver and are risk factors for aggravating the disease course of COVID-19. In fact, liver diseases are currently a major global health problem. There is a huge range of liver diseases and non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic condition, which in some patients progresses to cirrhosis and liver cancer. Currently, substantial efforts are being made to better understand NAFLD, especially, because there is no U.S. Food and Drug Administration (FDA)-approved pharmacological therapy. To explore this disease, metabolomics is the most recently developed omics technology after genomics, transcriptomics, and proteomics. Metabolomics is the large-scale analysis of molecules, known as metabolites that are intermediate or end products of metabolism found within cells, tissues, and biofluids. This technology has a very high potential to identify biomarker candidates for the future development of new therapeutics. The book features articles that address metabolomics technology and its use to document different liver functions and dysfunctions, with a major focus on NAFLD.
Medicine --- nonalcoholic fatty liver disease --- nonalcoholic steatohepatitis --- Fibrosis --- Liver biopsy --- Genomics --- Metabolomics --- Proteomics --- Transcriptomics --- nicotinamide --- NAFLD --- steatosis --- heat stress --- primary mouse hepatocytes --- metabolic profile --- GC-MS --- multivariate statistical analysis --- arachidonic acid --- docosahexaenoic acid --- inflammation --- fibrosis --- lipidomics --- mass spectrometry --- in vitro --- HepaRG --- sodium saccharin --- reference toxicants --- de novo lipogenesis --- carbohydrate response element-binding protein --- ChREBP --- diabetes --- glucose production --- glycogen --- glycolysis --- glycogen storage disease type I --- hexosamine --- pentose phosphate pathway --- acupuncture --- imflammation --- lipid metabolism --- oxidative stress --- metabolomics quantitative profiling --- 1H-NMR spectroscopy --- liver --- bile acids --- metabolomics --- rat plasma --- tandem mass spectrometry --- liquid chromatography --- acetaminophen --- hepatotoxicity --- biomarker --- premalignant --- alcoholic liver disease --- cholestasis --- cirrhosis --- NAFL --- NASH --- standard operating procedures --- urine --- blood --- feces --- tissue --- cells --- liver function --- nonalcoholic fatty liver --- liquid chromatography-mass spectrometry --- nuclear magnetic resonance spectroscopy --- metabolic pathway --- non-alcoholic fatty liver disease --- non-alcoholic steatohepatitis --- transcription factors --- metabolic stress --- lipid homeostasis --- glucose homeostasis --- nonalcoholic fatty liver disease --- nonalcoholic steatohepatitis --- Fibrosis --- Liver biopsy --- Genomics --- Metabolomics --- Proteomics --- Transcriptomics --- nicotinamide --- NAFLD --- steatosis --- heat stress --- primary mouse hepatocytes --- metabolic profile --- GC-MS --- multivariate statistical analysis --- arachidonic acid --- docosahexaenoic acid --- inflammation --- fibrosis --- lipidomics --- mass spectrometry --- in vitro --- HepaRG --- sodium saccharin --- reference toxicants --- de novo lipogenesis --- carbohydrate response element-binding protein --- ChREBP --- diabetes --- glucose production --- glycogen --- glycolysis --- glycogen storage disease type I --- hexosamine --- pentose phosphate pathway --- acupuncture --- imflammation --- lipid metabolism --- oxidative stress --- metabolomics quantitative profiling --- 1H-NMR spectroscopy --- liver --- bile acids --- metabolomics --- rat plasma --- tandem mass spectrometry --- liquid chromatography --- acetaminophen --- hepatotoxicity --- biomarker --- premalignant --- alcoholic liver disease --- cholestasis --- cirrhosis --- NAFL --- NASH --- standard operating procedures --- urine --- blood --- feces --- tissue --- cells --- liver function --- nonalcoholic fatty liver --- liquid chromatography-mass spectrometry --- nuclear magnetic resonance spectroscopy --- metabolic pathway --- non-alcoholic fatty liver disease --- non-alcoholic steatohepatitis --- transcription factors --- metabolic stress --- lipid homeostasis --- glucose homeostasis
Listing 1 - 10 of 10 |
Sort by
|